We've ceased enrolment & dosing in the $CHM CDH17 Phase 1 study following a second dose-limiting toxicity at Dose Level 3. Anti-tumour activity observed supports CDH17 as a valid target for further development, with a focus on an in vivo approach. app.sharelinktechnologies.co…

Our CEO, Rebecca McQualter, presented at last week’s TechKnow Invest Roadshow held in Melbourne & Sydney. A recording of the presentation is now available. View Rebecca’s presentation here: tinyurl.com/nhc48m3w #CHM #Biotech #CellTherapy #ClinicalTrials #TechKnow2026 #ASX

Our Quarterly Activities Report for the period ending 30 June 2026 has been released. View the full $CHM report: app.sharelinktechnologies.co…

We've received $1.62M advance on our FY2026 R&D tax incentive. The funding will support our ongoing Phase 1/2 clinical trial activities and general working capital as we continue our previously announced Strategic Review. app.sharelinktechnologies.co…

Investor Presentation: July 2026 View the full $CHM Presentation here: app.sharelinktechnologies.co…

Yesterday, our CEO Dr Rebecca McQualter presented at the Melbourne TechKnow 2026 Roadshow, providing an update on $CHM's clinical-stage cell therapy portfolio, including our CDH17 CAR-T Phase 1/2 trial and CORE-NK platform. We look forward to presenting in Sydney tomorrow.

We're looking forward to attending the TechKnow Invest Roadshow in Melbourne and Sydney on 27 & 29 July, where our CEO, Dr Rebecca McQualter, will present an update on Chimeric Therapeutics. Monday, 27 July 2026 2:30pm, Sydney Wednesday, 29 July 2026 9:00am, Melbourne $CHM

We've treated 4 patients at the highest dose, Dose Level 3, in our ongoing Phase 1/2 clinical trial of $CHM CDH17. New preliminary data from 2 patients shows encouraging anti-tumour activity, including tumour shrinkage of 17% to 40% in individual lesions. tinyurl.com/mum3jbfa

Our CEO Dr Rebecca McQualter will be speaking at ISCT ANZ 2026 in Melbourne as part of the Commercial Workstream session, "Capital Raising to FIH to Path to Commercialisation." Tuesday, 21 July, 4:45pm to 5:45pm. Learn more: isctglobal.org/ #ISCTANZ2026 $CHM

We're proud to announce that $CHM has been recognised with the Regional Leadership Award – CGT Company of the Year (Australia & New Zealand) at the Asia-Pacific CGT Excellence Awards 2026. Thank you to the organisers & congratulations to all of this year's finalists and winners.

This Bowel Cancer Awareness Month, we recognise the impact of bowel cancer across Australia. @Chimeric is advancing $CHM CDH17, a CAR T-cell therapy being investigated in colorectal & other gastrointestinal cancers. We're focused on developing new treatment options for patients.

Chimeric CAR T therapy delivers durable disease control in early GI cancer trial | $CHM Media coverage by @AusBiotech biotechdispatch.com.au/news/… l

We've achieved 82% stable disease per RECIST, with 9 of 11 evaluable patients achieving stable disease. $CHM CDH17 expanded & persisted in all treated patients, with evidence of disease control in heavily pre-treated metastatic cancer patients. app.sharelinktechnologies.co…

We’re in Philadelphia visiting Minaris for a closer look at a manufacturing run for $CHM CDH17. CEO Dr Rebecca McQualter and Head of Manufacturing Dr Agathe Bourgogne visited the site as CHM CDH17 progresses through Phase 1/2 clinical development in gastrointestinal cancers.

“We’re just about to hit a very big inflection point.” From our CEO Dr Rebecca McQualter, speaking with @wholesaleinvest. 🎥 Watch the $CHM interview below. youtu.be/Nkg4zaS36Sk?si=_NCx… #CellTherapy #Oncology #Biotech #ASX #Chimeric

Our Quarterly Activities Report for the period ending 31 March 2026 has been released. View the full $CHM report: app.sharelinktechnologies.co…

Top 10 at 11: Chimeric has complete response in 60pc of leukemia cohort | $CHM Medica coverage by @StockheadAU. stockhead.com.au/news/top-10…

We’ve achieved 60% CR/CRi in the ADVENT-AML NCT05834244 Phase 1B clinical trial, with 25 patients enrolled, 60% have demonstrated complete responses. High risk, frontline patients are being treated with CHM CORE-NK + standard of care. app.sharelinktechnologies.co… $CHM #Biotech

Our CEO Dr Rebecca McQualter, will join industry leaders in #Rome this month to moderate “From Phase 1 to BLA: Early Decisions that Impact Global Expansion” on 29 April, 11:30am CET. The panel includes leaders from Autolus Therapeutics, Cabaletta Bio and Cellares. $CHM

From CEO Dr Rebecca McQualter at the NWR Healthcare Conference: A $CHM CDH17 patient has reached 15 months with no new tumours, maintaining chemotherapy-free progression-free survival. CHM CDH17 has now advanced to Dose Level 3. 🎥 Watch the full replay: youtube.com/watch?v=CxOg6sU7…